A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
How ECOPEACE uses autonomous robots and data to monitor and maintain urban water bodies.
Updated
January 23, 2026 10:41 AM
A school of fish swimming among debris and waste. PHOTO: UNSPLASH
South Korea–based water technology company ECOPEACE is working on a practical challenge many cities face today: keeping urban water bodies clean as pollution and algae growth become more frequent. Rather than relying on periodic cleanup drives, the company focuses on systems that can monitor and manage water conditions on an ongoing basis.
At the core of ECOPEACE’s work are autonomous water-cleanup robots known as ECOBOT. These machines operate directly on lakes, reservoirs and rivers, removing algae and surface waste while also collecting information about water quality. The idea is to combine cleaning with constant observation so changes in water conditions do not go unnoticed.
Alongside the robots, ECOPEACE uses a filtration and treatment system designed to process polluted water continuously. This system filters out contaminants using fine metal filters and treats the water using electrical processes. It also cleans itself automatically, which allows it to run for long periods without frequent manual maintenance.
The role of AI in this setup is largely about decision-making rather than direct control. Sensors placed across the water body collect data such as pollution levels and water quality indicators. The software then analyses this data to spot early signs of issues like algae growth. Based on these patterns, the system adjusts how the robots and filtration units operate, such as changing treatment intensity or water flow. In simple terms, the technology helps the system respond sooner instead of waiting for visible problems to appear.
ECOPEACE has already deployed these systems across several reservoirs, rivers and urban waterways in South Korea. Those projects have helped refine how the robots, sensors and software work together in real environments rather than controlled test sites.
Building on that experience, the company has begun expanding beyond Korea. It is currently running pilot and proof-of-concept projects in Singapore and the United Arab Emirates. These deployments are testing how the technology performs in dense urban settings where waterways are closely linked to public health, infrastructure and daily city life.
Both regions have invested heavily in smart city initiatives and water management, making them suitable test beds for automated monitoring and cleanup systems. The pilots focus on algae control, surface cleaning and real-time tracking of water quality rather than large-scale rollout.
As cities continue to grow and climate-related pressures on water systems increase, managing waterways is becoming less about occasional intervention and more about continuous oversight. ECOPEACE’s approach reflects that shift by using automation and data to address problems early and reduce the need for reactive cleanup later.